Starting from 2023, Medicilon are hosting a series of webinars with a wide range of critical topics in biotech industry, including IP strategies, licensing, M&A, investment, due diligence, finance, company management, the business environment between United States and China, as well as how Medicilon can support with its 20 years of establishment and new research and technology platforms.
During the webinars, Medicilon invites a group of senior industrial experts and executives in related fields to systematically introduce the ideas and key elements, share their experience, and conduct the in-depth discussions.
Speakers shared "Building a strong patent portfolio to gain market competitive advantages" in the A.C.E. Seminar 1. They will share multiple topics on "PROTAC Platform & Its Application Case in Drug Discovery" and "Patent enforcement and clearance for freedom-to-operate in the U.S." in the A.C.E. Seminar 2. We sincerely invite you to join us!
Time
March 4,2023 09:00-10:00(ET)
March 4,2023 22:00-23:00 (Beijing)
Agenda
About Medicilon
Medicilon is a professional pharmaceutical preclinical integrated R&D service contract research organization (CRO), providing a full range of one-stop new drug R&D services, in compliance with Chinese and international filing standards, to pharmaceutical companies and research institutions around the world. Our services cover the entire process of preclinical new drug research, including drug discovery, pharmacology research and preclinical research.
We focus on the needs of innovation and development of global pharmaceutical industry, based on the key aspects of R&D of innovative drug, and build a comprehensive technology platform covering drug discovery, pharmacological research and preclinical research key technologies with our rich experience in serving the Chinese and international biopharmaceutical industry.
For enquiries, please email marketing@medicilon.com.
Click to register
#ACE #patent enforcement #patent clearance
Feb 1, 2023 20:00-21:00 (ET)
Feb 2, 2023 9:00-10:00 (Beijing)